Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CHROMOBLASTOMYCOSIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 451 records · Page 25Linked to original sources
PubMed1975

Chromomycosis in the toad (Bufo marinus) and a comparison of the etiologic agent with fungi causing human chromomycosis.

Of 75 toads (Bufo marinus) 2 were found infected by black molds. The internal organs of these animals had granulomatous lesions containing brown fungi identical to those found in human chromomycosis. Cultures gave rise to slow-growing black molds but all attempts to induce sporulation failed. The fungi did not grow at 36 degrees C or above and failed to hydrolyse gelatin or casein. Immunodiffusion and immunoelectrophoresis revealed that both isolates were identical and shared common antigens with the recognized human pathogens P. pedrosoi, P. verrucosa and C. carrioni. The findings are compared with other reports of black mold infections in amphibians.

Animals↗
PubMed1990

Verrucous lesions in children in the tropics.

A wide variety of skin disorders in children are encountered by doctors practising in tropical countries. While some of them are common and pose little difficulty in their management, a few are uncommon, run a protracted course and cause errors in diagnosis. Two patients--one with cutaneous tuberculosis and the other with chromomycosis--are described and illustrate the importance of early and prompt detection of disease in children.

Adult↗
PubMed1991

Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case.

Cerebral phaeohyphomycosis (also referred to as cerebral chromomycosis), one of the diseases caused by the dematiaceous (black) fungi, is most commonly caused by Cladosporium trichoides (referred to by some as Xylohypha bantiana) and is a rare disease, with 31 culture-proven cases reported to date. Although most cases have occurred in immunocompetent hosts, recent experimental evidence suggests that host immunosuppression may predispose patients to the disease. The authors report a case of fatal cerebral phaeohyphomycosis in a liver transplant patient, the first to occur in a transplant patient of any type, to the best of the authors' knowledge. This case provides support for the hypothesis that immunosuppressed patients may be at increased risk for development of this disease.

Brain Diseases↗
PubMedDate not supplied

A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis.

Itraconazole was administered orally to two patients with sporotrichosis, 10 patients with paracoccidioidomycosis, three with mycetomas (due to Madurella grisea, Streptomyces madurae, and Pseudochaetosphaeronema larense, respectively), nine with chromomycosis due to Cladosporium carrionii, five with chromomycosis due to Fonsecaea pedrosoi and five with leishmaniasis (including one with the nodular disseminated form). The clinical and laboratory tests showed excellent tolerance to the drug with a total absence of adverse reactions. Satisfactory results were achieved against paracoccidioidomycosis, sporotrichosis, and chromomycosis due to C. carrionii (apparent cure was achieved in a short time). Encouraging improvement was noted in the treatment of mycetoma due to M. grisea. Among the five cases of leishmaniasis, a complete clearing was achieved in one and an encouraging improvement in two, including the one with the nodular disseminated form. Two patients with F. pedrosoi infection were apparently cured after the addition of thermotherapy and flucytosine, respectively, to the treatment regimen.

Adolescent↗
PubMedDate not supplied

Itraconazole for deep mycoses: preliminary experience in Mexico.

Itraconazole has been used as oral therapy for deep mycoses since July 1984 in our institution. So far, therapy has been evaluated for eight patients: one with cutaneous coccidioidomycosis; two with chromomycosis (Fonsecaea pedrosoi); and five with sporotrichosis (three fixed, one lymphangitic, and one disseminated). Clinical and mycologic evaluations were done at the beginning of treatment, 15 days after the initiation of treatment, and monthly thereafter. Dosage was 100-200 mg per day, and duration of treatment was based on response. The cases of coccidioidomycosis and lymphangitic sporotrichosis were mycologically cured after two and seven months of treatment with 100 mg per day, respectively. The six other patients required higher doses. Two patients with sporotrichosis and one with chromomycosis were cured, and one patient with sporotrichosis and one with chromomycosis were markedly improved. In one patient with sporotrichosis, treatment was discontinued because of the slow response. No adverse reactions to treatment were reported.

Adult↗